ExodusPoint Capital Management’s Aptose Biosciences, Inc. APTO Stock Holding History

ExodusPoint Capital Management’s Portfolio APTO Stock Details APTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-82	Closed	-$123K	–	2829
2021 Q2	$123K	Buy	+82	New	+$179K	﹤0.01%	2105

Other funds holding APTO

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

ExodusPoint Capital Management's APTO Position: Q3 2021 in Review

ExodusPoint Capital Management sold out of Aptose Biosciences, Inc. (APTO) in Q3 2021, closing a stake of 82 shares — an estimated $123K sold.

ExodusPoint Capital Management first reported a position in APTO in Q2 2021 and held it in 1 quarter. The position peaked at $123K in Q2 2021. 64 funds tracked by Wall St. Rank hold APTO as of Q3 2021.

ExodusPoint Capital Management reported no remaining Aptose Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
ExodusPoint Capital Management sold 82 Aptose Biosciences, Inc. shares in Q3 2021, an estimated $123K.
ExodusPoint Capital Management first reported a position in Aptose Biosciences, Inc. in Q2 2021 and held it in 1 quarter.
ExodusPoint Capital Management's Aptose Biosciences, Inc. position peaked at $123K in Q2 2021.
64 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.